

Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management

[J] Evidence review for managing intracranial
hypertension

NICE guideline NG228

Methods, evidence and recommendations

November 2022

Final

*National Institute for Health and Care
Excellence*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2022. All rights reserved. Subject to [Notice of rights](#).

ISBN: 978-1-4731-4815-4

Contents

1	Managing intracranial hypertension	5
1.1	Review question: What is the clinical and cost effectiveness of options for managing intracranial hypertension?	5
1.2	Introduction	5
1.3	PICO table	5
1.4	Clinical evidence	6
1.4.1	Included studies	6
1.4.2	Excluded studies	6
1.4.3	Summary of clinical studies included in the evidence review	7
1.4.4	Quality assessment of clinical studies included in the evidence review	9
1.5	Economic evidence	11
1.5.1	Included studies	11
1.5.2	Excluded studies	11
1.5.3	Unit costs	11
1.6	Evidence statements	11
1.6.1	Health economic evidence statements	11
1.7	The committee's discussion of the evidence	11
1.7.1	Interpreting the evidence	11
1.7.2	Cost effectiveness and resource use	12
1.7.3	Other factors the committee took into account	13
	Appendices	19
	Appendix A: Review protocols	19
	Appendix B: Literature search strategies	26
	B.1 Clinical search literature search strategy	26
	B.2 Health Economics literature search strategy	31
	Appendix C: Clinical evidence selection	35
	Appendix D: Clinical evidence tables	36
	Appendix E: Forest plots	40
	Appendix F: Minimal Important Difference for continuous outcomes	41
	Appendix G: GRADE tables	42
	Appendix H: Health economic evidence selection	44
	Appendix I: Health economic evidence tables	45
	Appendix J: Excluded studies	46
	J.1 Excluded clinical studies	46
	J.2 Excluded health economic studies	47
	Appendix K: Research recommendations	48

1 Managing intracranial hypertension

Evidence review underpinning research recommendations in the NICE guideline.

1.1 Review question: What is the clinical and cost effectiveness of options for managing intracranial hypertension?

1.2 Introduction

In people with subarachnoid haemorrhage, intracranial pressure may be increased by hydrocephalus, haematoma, infection, or cerebral oedema. Raised intracranial pressure (intracranial hypertension) can impede blood flow to the brain and contribute to brain injury, in spite of a normal systemic blood pressure.

Several treatments for intracranial hypertension are in clinical use but there is variation in practice between neurosurgical centres. This review assesses the evidence to support medical and surgical interventions to treat intracranial hypertension.

1.3 PICO table

For full details see the review protocol in Appendix A:.

Table 1: PICO characteristics of review question

Population	Inclusion: Adults (16 and older) with intracranial hypertension and a confirmed subarachnoid haemorrhage caused by a suspected or confirmed ruptured aneurysm.
Intervention	<ul style="list-style-type: none">• Diuretics• Hypertonic saline• Surgical interventions:<ul style="list-style-type: none">○ Decompressive Craniectomy○ External ventricular drain• Sedation• Hypertensive therapy
Comparison	Comparators: <ul style="list-style-type: none">• To each other (within and between class comparison)• To no treatment
Outcomes	Critical outcomes: <ul style="list-style-type: none">• Mortality• Health and social-related quality of life (any validated measure)• Degree of disability or dependence in daily activities, (any validated measure e.g. Modified Rankin Scale and patient-reported outcome measures) Important outcomes: <ul style="list-style-type: none">• Subsequent subarachnoid haemorrhage• Return to daily activity (e.g. work, driving)• Complications of intervention (any)• Change in intracranial pressure
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.

If insufficient RCT evidence is available, non-randomised studies will be considered if they adjust for key confounders (age), starting with prospective cohort studies.

1.4 Clinical evidence

1.4.1 Included studies

Two studies were included in the review;^{6, 38} these are summarised in Table 2 below. Evidence from these studies is summarised in the clinical evidence summary below (Table 3).

1.4.2 Excluded studies

See the excluded studies list in Appendix J:.

1.4.3 Summary of clinical studies included in the evidence review

Table 2: Summary of studies included in the evidence review

Study	Intervention and comparison	Population	Outcomes	Comments
Bentsen 2006 ⁶	<p>Hypertonic saline - was a 7.2% saline in 6% hydroxyethyl starch 200/0.5 solution (HyperHAES, Fresenius Kabi AG) The observation period lasted from 10 min before until 210 min after the start of the infusion. Need for rescue treatment was defined by treatment failure limits for ICP and CPP, which were an ICP of >20> 20 mm HG and a CPP of 60 <60 mmHG. Unless these limits were reached during the observation period, the ventilation variables were kept unaltered, the infusion rates vasopressors, analgesics, sedatives, and fluids were stable, the resistance in the external ventricular drainage (EVD) was unchanged, and the patients were neither stimulated or moved.</p> <p>N=11</p> <p>Control (placebo) - was 0.9% saline solution (Fresenius Kabi AG, Bad Hamburg v.d.h), Germany. The observation period lasted from 10 mins before until 210 mins after the</p>	<p>Included intensive care patients with an acute spontaneous SAH with stable ICP in the range 10 - 20 mmHg. They needed to be >18 years of age, sedated, mechanically ventilated, have stable hemodynamics and serum sodium of <160 mmol/L</p> <p>Age: Intervention Group – 50.1 (10.5) Placebo group – 55.2 (10.8)</p>	<ul style="list-style-type: none"> Intracranial pressure 	RCT

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>start of the infusion. Need for rescue treatment was defined by treatment failure limits for ICP and CPP, which were an ICP of >20> 20 mm HG and a CPP of 60 <60 mmHG. Unless these limits were reached during the observation period, the ventilation variables were kept unaltered, the infusion rates vasopressors, analgesics, sedatives, and fluids were stable, the resistance in the external ventricular drainage (EVD) was unchanged, and the patients were neither stimulated or moved.</p> <p>N=11</p> <p>Follow-up: 210 minutes</p>			
Nagel 2009 ³⁸	<p>Decompressive craniectomy - Hemicraniectomy was performed in median on day 4(2-6) after SAH, in 2 of the 7 patients early after SAH. In 4 patients (57%) a dilating pupil was observed shortly before hemicraniectomy.</p> <p>N=7</p> <p>Control: Patients who did not received decompressive craniectomy</p> <p>N=11</p>	<p>Any SAH patient developing intracranial hypertension with ICP values ≥ 20 mmHg for at least >6h after SAH and requiring treatment of elevated ICP was included. aSAH confirmed by CT; cerebral angiogram demonstrating intracranial aneurysm; patients underwent clipping followed by intraoperative insertion of the micro-dialysis catheter or patients underwent endovascular therapy of an aneurysm from the anterior</p>	<ul style="list-style-type: none"> • Mortality • GOS (Glasgow outcome scale) 1-2 • GOS (Glasgow outcome scale) 3 • GOS (Glasgow outcome scale) 4-5 	<p>Retrospective cohort study</p> <p>Mean age of patients was not significantly different between groups.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	Follow-up: 1 year	circulation and additionally had an external ventricular drainage placed, so catheter placement through the existing burr hole allowed monitoring of the anterior cerebral artery territory. Age: Intervention group - 48(3.4) Control group 52(3.5)		

See Appendix D: for full evidence tables.

1.4.4 Quality assessment of clinical studies included in the evidence review

Table 3: Clinical evidence summary: Hypertonic saline vs placebo

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Placebo	Risk difference with Hypertonic Saline (95% CI)
Change in intracranial pressure	22 (1 study) 210 minutes	⊕⊕⊕⊕ HIGH		The mean change intracranial hypertension in the control groups was -0.3 mmHg	The mean change intracranial hypertension in the intervention groups was 3 lower mmHg (4.72 to 1.28 lower)

Table 4: Clinical evidence summary: Decompressive craniectomy vs no decompressive craniectomy

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with no additional treatment	Risk difference with decompressive craniectomy (95% CI)
Mortality -	18 (1 study) death during hospitalisation	⊕⊕⊕⊕ VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.79 (0.38 to 1.64)	727 per 1000	153 fewer per 1000 (from 451 fewer to 465 more)
Mortality - (12 months)	18 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW ^{1,2} due to risk of bias, imprecision	Peto OR 13.08 (0.23 to 729.15)	0 per 1000	140 more per 1000 (from 150 fewer to 440 more)
GOS grade 1-2 (12 months) scale 1-5; high score represents positive outcome	16 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.04 (0.65 to 1.67)	800 per 1000	32 more per 1000 (from 280 fewer to 536 more)
GOS grade 3 (12 months) scale 1-5; high score represents positive outcome	16 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.67 (0.13 to 22)	100 per 1000	67 more per 1000 (from 87 fewer to 1000 more)
GOS grade 4-5 (12 months) scale 1-5; high score represents positive outcome	16 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW ¹ due to risk of bias	Peto OR 0.2 (0 to 11.57)	100 per 1000	78 fewer per 1000 (from 100 fewer to 462 more)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p>					

See Appendix G: for full GRADE tables.

1.5 Economic evidence

1.5.1 Included studies

No health economic studies were included.

1.5.2 Excluded studies

No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.

See also the health economic study selection flow chart in Appendix H:

1.5.3 Unit costs

Relevant unit costs are provided below to aid consideration of cost effectiveness.

Table 5: UK costs of treatments for decompressive craniectomy

Procedure	Description	Average cost
Decompressive craniectomy/ hemicraniotomy	Very Major Intracranial Procedures, 19 years and over [weighted average of NHS Reference Cost code AA52A-D]	£10,574

Source: NHS Reference Costs 2018/19⁴⁰

1.6 Evidence statements

1.6.1 Health economic evidence statements

No relevant economic evaluations were identified.

1.7 The committee's discussion of the evidence

1.7.1 Interpreting the evidence

1.7.1.1 The outcomes that matter most

The committee considered mortality, quality of life (Glasgow outcome scale) and degree of disability or dependence in daily activities to be critical outcomes for decision-making. Other important outcomes included subsequent subarachnoid haemorrhage, return to daily activity, complications of intervention and reduction in intracranial pressure.

1.7.1.2 The quality of the evidence

No evidence was identified for managing intracranial hypertension using diuretics, sedation, external ventricular drain or hypertensive therapy.

Limited evidence was identified from two studies for hypertonic saline and decompressive craniectomy. The very small size of the studies (ranging from 18 to 22 participants) limited confidence in the strength of the evidence. The quality of evidence varied from high to very low; most of the evidence was downgraded due to risk of bias and/or imprecision. The RCT reported high quality evidence for the outcome of intracranial pressure, however the committee agreed that the evidence from this small study was insufficiently powered for clinical outcomes and could not support a recommendation. The outcomes from the

retrospective cohort study were at a high risk of bias due to their study design and were also downgraded due to imprecision.

1.7.1.3 Benefits and harms

The anticipated benefit of treating intracranial hypertension is to reduce the risk of mortality and subsequent neurological deterioration.

Hypertonic saline vs placebo

The committee were aware that administration of hypertonic saline may reduce intracranial pressure but is associated with a risk of metabolic derangement. The committee noted evidence from 1 small RCT that hypertonic saline lowers intracranial pressure when compared with normal saline, but the quality and quantity of the evidence was too low to draw any conclusions on the benefits or harms of this treatment and so no clinical recommendation was made.

Decompressive craniectomy vs no additional treatment

Evidence from 1 small cohort study showed a reduction in mortality (during hospitalisation) and less disability (GOS) with decompressive craniectomy compared with no decompressive craniectomy. This benefit was not sustained and at twelve months the study reported an increase in mortality with decompressive craniectomy compared to no decompressive craniectomy. The committee considered that the quality and quantity of the evidence was too low to draw any firm conclusions.

The committee noted from their clinical experience that a lower rate of mortality, but a higher rate of disability might be expected with decompressive craniectomy. The committee highlighted that there are recognised risks to an invasive procedure such as decompressive craniectomy, including haemorrhagic, infective, and CSF related complications. The committee agreed that no recommendation could be made for decompressive craniectomy.

The committee agreed that raised intracranial pressure is common in patients with aSAH, but intracranial hypertension that impedes blood flow to the brain and contributes to brain injury is generally only seen in the sickest group. These patients are usually unconscious or require ventilation on an intensive care unit, and the anticipated benefit of treating intracranial hypertension in these patients is to reduce the risk of death and disability. However, the committee acknowledged that management of this heterogeneous population varies widely in current practice, with some clinicians advocating routine monitoring of intracranial pressure to guide intervention to lower intracranial pressure and maintain cerebral perfusion (such as CSF drainage, hypertonic saline, or vasopressor therapy). By contrast, other clinicians favour management without intracranial pressure measurement.

The committee discussed the options for monitoring intracranial pressure and managing intracranial hypertension but could not agree whether intracranial pressure should be routinely measured or how raised intracranial pressure should be managed. The committee was therefore unable to make a consensus recommendation.

As the evidence available for this review and for the review on monitoring intracranial pressure (evidence review 1) was limited, the committee decided to make a research recommendation to assess the clinical and cost effectiveness of interventions to monitor and reduce intracranial pressure in unconscious or ventilated people with aSAH in whom the poor clinical condition is attributed at least partly to raised intracranial pressure.

1.7.2 Cost effectiveness and resource use.

No published economic evaluations were identified for this review. Unit costs were presented to the committee for consideration of cost effectiveness. However, due to a lack of clinical

evidence the committee could not determine the clinical effectiveness of interventions to manage intracranial hypertension and therefore the cost effectiveness could not be assessed.

Due to the lack of evidence the committee made a research recommendation and therefore there will be no resource impact.

1.7.3 Other factors the committee took into account

There was no consensus within the committee whether intracranial pressure should be routinely measured or how raised intracranial pressure should be managed. The committee recognised the difference in management between traumatic brain injury and primary vascular injuries of the brain. It was noted by the committee that in traumatic brain injury, measuring intracranial pressure is a routine practice whereas in vascular injuries it is seldom performed. The committee added that there is significant variation in how intracranial hypertension is managed. A number of centres monitor and manage intracranial hypertension in aSAH in a manner similar to that for traumatic brain injury.

Due to the lack of evidence available for this review and for the review on monitoring intracranial pressure, the committee made a research recommendation to assess the impact of routine monitoring of intracranial hypertension on subsequent management and outcome in people with aneurysmal SAH who are unconscious or ventilated on ICU (see Appendix K).

References

1. Al-Rawi PG, Tseng MY, Richards HK, Nortje J, Timofeev I, Matta BF et al. Hypertonic saline in patients with poor-grade subarachnoid hemorrhage improves cerebral blood flow, brain tissue oxygen, and pH. *Stroke*. 2010; 41(1):122-128
2. Alotaibi NM, Elkarim GA, Samuel N, Ayling OGS, Guha D, Fallah A et al. Effects of decompressive craniectomy on functional outcomes and death in poor-grade aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *Journal of Neurosurgery*. 2017; 127(6):1315-1325
3. Asaad SK, Bjarkam CR. The Aalborg Bolt-Connected Drain (ABCD) study: a prospective comparison of tunnelled and bolt-connected external ventricular drains. *Acta Neurochirurgica*. 2019; 161(1):33-39
4. Bakar B, Sumer MM, Tekkok IH. Decompressive craniectomy for intractable intracranial hypertension. *Journal of Clinical and Analytical Medicine*. 2012; 3(4):383-387
5. Battison C, Andrews PJ, Graham C, Petty T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. *Critical Care Medicine*. 2005; 33(1):196-202; discussion 257-258
6. Bentsen G, Breivik H, Lundar T, Stubhaug A. Hypertonic saline (7.2%) in 6% hydroxyethyl starch reduces intracranial pressure and improves hemodynamics in a placebo-controlled study involving stable patients with subarachnoid hemorrhage. *Critical Care Medicine*. 2006; 34(12):2912-2917
7. Bentsen G, Breivik H, Lundar T, Stubhaug A. Predictable reduction of intracranial hypertension with hypertonic saline hydroxyethyl starch: a prospective clinical trial in critically ill patients with subarachnoid haemorrhage. *Acta Anaesthesiologica Scandinavica*. 2004; 48(9):1089-1095
8. Bundgaard H, von Oettingen G, Jorgensen HA, Jensen K, Cold GE. Effects of dihydroergotamine on intracranial pressure, cerebral blood flow, and cerebral metabolism in patients undergoing craniotomy for brain tumors. *Journal of Neurosurgical Anesthesiology*. 2001; 13(3):195-201
9. Burger R, Duncker D, Uzma N, Rohde V. Decompressive craniotomy: durotomy instead of duroplasty to reduce prolonged ICP elevation. *Acta Neurochirurgica - Supplement*. 2008; 102:93-97
10. Buschmann U, Yonekawa Y, Fortunati M, Cesnulis E, Keller E. Decompressive hemicraniectomy in patients with subarachnoid hemorrhage and intractable intracranial hypertension. *Acta Neurochirurgica*. 2007; 149(1):59-65
11. Carandini T, Bozzano V, Scarpini E, Montano N, Solbiati M. Intensive versus standard lowering of blood pressure in the acute phase of intracranial haemorrhage: a systematic review and meta-analysis. *Internal and Emergency Medicine*. 2018; 13(1):95-105
12. Cole CD, Gottfried ON, Gupta DK, Couldwell WT. Total intravenous anesthesia: advantages for intracranial surgery. *Neurosurgery*. 2007; 61(5 Suppl 2):369-377; discussion 377-368
13. Cossu G, Messerer M, Stocchetti N, Levivier M, Daniel RT, Oddo M. Intracranial pressure and outcome in critically ill patients with aneurysmal subarachnoid hemorrhage: a systematic review. *Minerva Anestesiologica*. 2016; 82(6):684-696

14. D'Ambrosio AL, Sughrue ME, Yorgason JG, Mocco JD, Kreiter KT, Mayer SA et al. Decompressive hemicraniectomy for poor-grade aneurysmal subarachnoid hemorrhage patients with associated intracerebral hemorrhage: clinical outcome and quality of life assessment. *Neurosurgery*. 2005; 56(1):12-19; discussion 19-20
15. Dai HY, Yang YS, Guo FQ, Liu J, Yu NW. Effects of nimodipine on nervous functions, ability of daily life and plasma neuron-specific enolase of patients with hypertensive cerebral hemorrhage. *Chinese Journal of Clinical Rehabilitation*. 2005; 9(1):180-182
16. Dorfer C, Frick A, Knosp E, Gruber A. Decompressive hemicraniectomy after aneurysmal subarachnoid hemorrhage. *World Neurosurgery*. 2010; 74(4-5):465-471
17. Eide PK, Bentsen G, Sorteberg AG, Marthinsen PB, Stubhaug A, Sorteberg W. A randomized and blinded single-center trial comparing the effect of intracranial pressure and intracranial pressure wave amplitude-guided intensive care management on early clinical state and 12-month outcome in patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 2011; 69(5):1105-1115
18. Froelich M, Ni Q, Wess C, Ougorets I, Hartl R. Continuous hypertonic saline therapy and the occurrence of complications in neurocritically ill patients. *Critical Care Medicine*. 2009; 37(4):1433-1441
19. Graetz D, Nagel A, Schlenk F, Sakowitz O, Vajkoczy P, Sarrafzadeh A. High ICP as trigger of proinflammatory IL-6 cytokine activation in aneurysmal subarachnoid hemorrhage. *Neurological Research*. 2010; 32(7):728-735
20. Hauer EM, Stark D, Staykov D, Steigleder T, Schwab S, Bardutzky J. Early continuous hypertonic saline infusion in patients with severe cerebrovascular disease. *Critical Care Medicine*. 2011; 39(7):1766-1772
21. Hayashi M, Kobayashi H, Kawano H, Handa Y, Hirose S. Treatment of systemic hypertension and intracranial hypertension in cases of brain hemorrhage. *Stroke*. 1988; 19(3):314-321
22. Helbok R, Kurtz P, Schmidt JM, Stuart RM, Fernandez L, Malhotra R et al. Effect of mannitol on brain metabolism and tissue oxygenation in severe haemorrhagic stroke. *Journal of Neurology, Neurosurgery and Psychiatry*. 2011; 82(4):378-383
23. Heuer GG, Smith MJ, Elliott JP, Winn HR, LeRoux PD. Relationship between intracranial pressure and other clinical variables in patients with aneurysmal subarachnoid hemorrhage. *Journal of Neurosurgery*. 2004; 101(3):408-416
24. Horn P, Munch E, Vajkoczy P, Herrmann P, Quintel M, Schilling L et al. Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. *Neurological Research*. 1999; 21(8):758-764
25. Infanti JL. Challenging the gold standard: should mannitol remain our first-line defense against intracranial hypertension? *Journal of Neuroscience Nursing*. 2008; 40(6):362-368
26. Jagersberg M, Schaller C, Bostrom J, Schatlo B, Kotowski M, Thees C. Simultaneous bedside assessment of global cerebral blood flow and effective cerebral perfusion pressure in patients with intracranial hypertension. *Neurocritical Care*. 2010; 12(2):225-233
27. Karnatovskaia LV, Lee AS, Festic E, Kramer CL, Freeman WD. Effect of prolonged therapeutic hypothermia on intracranial pressure, organ function, and hospital outcomes among patients with aneurysmal subarachnoid hemorrhage. *Neurocritical Care*. 2014; 21(3):451-461

28. Kim JS, Cheong JH, Ryu JI, Kim JM, Kim CH. Bone flap resorption following cranioplasty after decompressive craniectomy: preliminary report. *Korean Journal of Neurotrauma*. 2015; 11(1):1-5
29. Lewandowski-Belfer JJ, Patel AV, Darracott RM, Jackson DA, Nordeen JD, Freeman WD. Safety and efficacy of repeated doses of 14.6 or 23.4 % hypertonic saline for refractory intracranial hypertension. *Neurocritical Care*. 2014; 20(3):436-442
30. Lewis A, Taylor Kimberly W. Prediction of ventriculoperitoneal shunt placement based on type of failure during external ventricular drain wean. *Clinical Neurology and Neurosurgery*. 2014; 125:109-113
31. Lo YT, See AAQ, King NKK. Decompressive craniectomy in spontaneous intracerebral hemorrhage: a case-control study. *World Neurosurgery*. 2017; 103:815-820.e812
32. Malmivaara K, Ohman J, Kivisaari R, Hernesniemi J, Siironen J. Cost-effectiveness of decompressive craniectomy in non-traumatic neurological emergencies. *European Journal of Neurology*. 2011; 18(3):402-409
33. Munch E, Weigel R, Schmiedek P, Schurer L. The Camino intracranial pressure device in clinical practice: reliability, handling characteristics and complications. *Acta Neurochirurgica*. 1998; 140(11):1113-1119; discussion 1119-1120
34. Murad A, Ghostine S, Colohan AR. Controlled lumbar drainage in medically refractory increased intracranial pressure. A safe and effective treatment. *Acta Neurochirurgica - Supplement*. 2008; 102:89-91
35. Murad A, Ghostine S, Colohan AR. Role of controlled lumbar CSF drainage for ICP control in aneurysmal SAH. *Acta Neurochirurgica - Supplement*. 2011; 110(Pt 2):183-187
36. Myles GL, Malkoff MD, Perry AG, Bucholz RD, Gomez CR. Therapeutic Intervention Scoring System used in the care of patients in pentobarbital-induced coma to determine nurse-patient ratios. *American Journal of Critical Care*. 1996; 5(1):74-79
37. Nagel A, Graetz D, Schink T, Frieler K, Sakowitz O, Vajkoczy P et al. Relevance of intracranial hypertension for cerebral metabolism in aneurysmal subarachnoid hemorrhage. *Clinical article. Journal of Neurosurgery*. 2009; 111(1):94-101
38. Nagel A, Graetz D, Vajkoczy P, Sarrafzadeh AS. Decompressive craniectomy in aneurysmal subarachnoid hemorrhage: relation to cerebral perfusion pressure and metabolism. *Neurocritical Care*. 2009; 11(3):384-394
39. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
40. NHS England and NHS Improvement. National cost collection for the NHS 2018-19. 2019. Available from: <https://improvement.nhs.uk/resources/national-cost-collection/> Last accessed: 01/04/2020.
41. Otani N, Nawashiro H, Wada K, Nagatani K, Takeuchi S, Kobayashi H et al. Surgical results after primary decompressive craniectomy in poor-grade aneurysmal subarachnoid hemorrhage. *Acta Neurochirurgica - Supplement*. 2013; 118:269-272
42. Otani N, Takasato Y, Masaoka H, Hayakawa T, Yoshino Y, Yatsushige H et al. Surgical outcome following decompressive craniectomy for poor-grade aneurysmal

- subarachnoid hemorrhage in patients with associated massive intracerebral or Sylvian hematomas. *Cerebrovascular Diseases*. 2008; 26(6):612-617
43. Pasarikovski CR, Alotaibi NM, Al-Mufti F, Macdonald RL. Hypertonic saline for increased intracranial pressure after aneurysmal subarachnoid hemorrhage: a systematic review. *World Neurosurgery*. 2017; 105:1-6
 44. Qureshi AI, Suarez JI. Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. *Critical Care Medicine*. 2000; 28(9):3301-3313
 45. Ravishankar N, Nuoman R, Amuluru K, El-Ghanem M, Thulasi V, Dangayach NS et al. Management strategies for intracranial pressure crises in subarachnoid hemorrhage. *Journal of Intensive Care Medicine*. 2020; 35(3):211-218
 46. Reddy P, Yeh YC. Use of injectable nicardipine for neurovascular indications. *Pharmacotherapy*. 2009; 29(4):398-409
 47. Roitberg BZ, Hardman J, Urbaniak K, Merchant A, Mangubat EZ, Alaraj A et al. Prospective randomized comparison of safety and efficacy of nicardipine and nitroprusside drip for control of hypertension in the neurosurgical intensive care unit. *Neurosurgery*. 2008; 63(1):115-120
 48. Schirmer CM, Hoit DA, Malek AM. Decompressive hemicraniectomy for the treatment of intractable intracranial hypertension after aneurysmal subarachnoid hemorrhage. *Stroke*. 2007; 38(3):987-992
 49. Schwarz S, Schwab S, Bertram M, Aschoff A, Hacke W. Effects of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke. *Stroke*. 1998; 29(8):1550-1555
 50. Shi Y, Kong X. Influence of mannitol on early enlargement of hematoma in hypertensive cerebral hemorrhage. *Chinese Medical Journal*. 2000; 80(11):849-851
 51. Stocchetti N, Parma A, Lamperti M, Songa V, Tognini L. Neurophysiological consequences of three tracheostomy techniques: a randomized study in neurosurgical patients. *Journal of Neurosurgical Anesthesiology*. 2000; 12(4):307-313
 52. Takeuchi S, Takasato Y, Masaoka H, Hayakawa T, Yatsushige H, Sugawara T. Simultaneous multiple hypertensive intracranial hemorrhages. *Journal of Clinical Neuroscience*. 2011; 18(9):1215-1218
 53. Tanrikulu L, Oez-Tanrikulu A, Weiss C, Scholz T, Schiefer J, Clusmann H et al. The bigger, the better? About the size of decompressive hemicraniectomies. *Clinical Neurology and Neurosurgery*. 2015; 135:15-21
 54. Thenier-Villa JL, Riveiro Rodriguez A, Gonzalez-Vargas PM, Martinez-Rolan RM, Gelabert-Gonzalez M, Badaoui Fernandez A et al. Effects of external ventricular drainage decompression of intracranial hypertension on rebleeding of brain aneurysms: a fluid structure interaction study. *Interdisciplinary Neurosurgery*. 2020; 19:100613
 55. Tietjen CS, Hurn PD, Ulatowski JA, Kirsch JR. Treatment modalities for hypertensive patients with intracranial pathology: options and risks. *Critical Care Medicine*. 1996; 24(2):311-322
 56. Tuettenberg J, Czabanka M, Horn P, Woitzik J, Barth M, Thome C et al. Clinical evaluation of the safety and efficacy of lumbar cerebrospinal fluid drainage for the treatment of refractory increased intracranial pressure. *Journal of Neurosurgery*. 2009; 110(6):1200-1208

57. Tuteja G, Uppal A, Strong J, Nguyen T, Pope K, Jenkins R et al. Interventions affecting blood pressure variability and outcomes after intubating patients with spontaneous intracranial hemorrhage. *American Journal of Emergency Medicine*. 2019; 37(9):1665-1671
58. Uozumi Y, Sakowitz O, Orakcioglu B, Santos E, Kentar M, Haux D et al. Decompressive craniectomy in patients with aneurysmal subarachnoid hemorrhage: a single-center matched-pair analysis. *Cerebrovascular Diseases*. 2014; 37(2):109-115
59. Villa F, Iacca C, Molinari AF, Giussani C, Aletti G, Pesenti A et al. Inhalation versus endovenous sedation in subarachnoid hemorrhage patients: effects on regional cerebral blood flow. *Critical Care Medicine*. 2012; 40(10):2797-2804
60. Wang G, Song J. Comprehensive nursing intervention effect in treating hypertensive cerebral hemorrhage by minimally invasive surgery. *Biomedical Research*. 2017; 28(20):9024-9027
61. Witherspoon B, Ashby NE. The use of mannitol and hypertonic saline therapies in patients with elevated intracranial pressure: a review of the evidence. *Nursing Clinics of North America*. 2017; 52(2):249-260
62. Won YD, Yoo DS, Kim KT, Kang SG, Lee SB, Kim DS et al. Cranioplasty effect on the cerebral hemodynamics and cardiac function. *Acta Neurochirurgica - Supplement*. 2008; 102:15-20
63. Woodcock J, Ropper AH, Kennedy SK. High dose barbiturates in non-traumatic brain swelling: ICP reduction and effect on outcome. *Stroke*. 1982; 13(6):785-787
64. Wykes V, Vindlacheruvu R. Intracranial pressure, cerebral blood flow and brain oedema. *Surgery*. 2015; 33(8):355-362
65. Xu C, Chen B, Xue L, Xia L, Yang X, Wei M et al. Randomized controlled study on the curative effects of twist-drill craniotomy and burr-hole craniotomy in the treatment of chronic subdural hematoma. *Experimental and Therapeutic Medicine*. 2018; 16:959-965
66. Yang G, Shao G. Clinical effect of minimally invasive intracranial hematoma in treating hypertensive cerebral hemorrhage. *Pakistan Journal of Medical Sciences*. 2016; 32(3):677-681
67. Zahid Z, Hashim L, Fang Y, Altaweel L, Sheridan M, Wang J. Hemicraniectomy versus induced hypothermia for the management of refractory intracranial hypertension: a retrospective review. *Neurocritical Care*. 2012; 17:S114
68. Zhao B, Zhao Y, Tan X, Cao Y, Wu J, Zhong M et al. Primary decompressive craniectomy for poor-grade middle cerebral artery aneurysms with associated intracerebral hemorrhage. *Clinical Neurology and Neurosurgery*. 2015; 133:1-5

Appendices

Appendix A: Review protocols

Table 6: Review protocol: Managing intracranial hypertension

ID	Field	Content
0.	PROSPERO registration number	CRD42019146786
1.	Review title	What is the clinical and cost effectiveness of options for managing intracranial hypertension?
2.	Review question	What is the clinical and cost effectiveness of options for managing intracranial hypertension?
3.	Objective	To determine which intervention to manage intracranial hypertension is the most clinically and cost-effective. Intracranial hypertension is recognised as a serious complication of aneurysmal subarachnoid haemorrhage associated with increased morbidity.
4.	Searches	<p>The following databases will be searched:</p> <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR) • Embase • MEDLINE <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> • English language only <p>The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review</p>
5.	Condition or domain being studied	Aneurysmal subarachnoid haemorrhage
6.	Population	<p>Inclusion: Adults (16 and older) with intracranial hypertension and a confirmed subarachnoid haemorrhage caused by a suspected or confirmed ruptured aneurysm.</p> <p>Exclusion:</p> <ul style="list-style-type: none"> • Adults with subarachnoid haemorrhage caused by head injury, ischaemic stroke or an arteriovenous malformation. • Children and young people aged 15 years and younger.
7.	Intervention/Exposure/Test	<ul style="list-style-type: none"> • Diuretics • Hypertonic saline • Surgical interventions:

		<ul style="list-style-type: none"> ○ Decompressive Craniectomy ○ External ventricular drain ● Sedation ● Hypertensive therapy
8.	Comparator/Reference standard/Confounding factors	<p>Comparators:</p> <ul style="list-style-type: none"> ● To each other (within and between class comparison) ● To no treatment
9.	Types of study to be included	<p>Randomised controlled trials (RCTs), systematic reviews of RCTs.</p> <p>If insufficient RCT evidence is available, non-randomised studies will be considered if they adjust for key confounders (age), starting with prospective cohort studies.</p>
10.	Other exclusion criteria	<p>Exclusions:</p> <ul style="list-style-type: none"> ● Intracranial hypertension due to hydrocephalus. ● Non- English language studies ● Abstracts will be excluded as it is expected there will be sufficient full text published studies available.
11.	Context	
12.	Primary outcomes (critical outcomes)	<ul style="list-style-type: none"> ● Mortality ● Health and social-related quality of life (any validated measure) ● Degree of disability or dependence in daily activities, (any validated measure e.g. Modified Rankin Scale and patient-reported outcome measures)
13.	Secondary outcomes (important outcomes)	<ul style="list-style-type: none"> ● Subsequent subarachnoid haemorrhage ● Return to daily activity (e.g. work, driving) ● Complications of intervention (any) ● Change in intracranial pressure <p>Outcomes will be grouped at <30 days, 30days-6 months, 6-12 months, and at yearly time-points thereafter.</p>
14.	Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>EviBASE will be used for data extraction.</p> <p>If not an intervention review, add: A standardised form will be used to extract data</p>

		from studies (see Developing NICE guidelines: the manual section 6.4).
15.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <ul style="list-style-type: none"> • Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS) • Randomised Controlled Trial: Cochrane RoB (2.0) • Non randomised study, including cohort studies: Cochrane ROBINS-I <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> • papers were included /excluded appropriately • a sample of the data extractions • correct methods are used to synthesise data • a sample of the risk of bias assessments <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
16.	Strategy for data synthesis	<ul style="list-style-type: none"> • Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). • GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias is tested for when there are more than 5 studies for an outcome. • The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group http://www.gradeworkinggroup.org/ • Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome. • Subgroups will be investigated separately if meta-analysed results show heterogeneity.
17.	Analysis of sub-groups	<p>Strata:</p> <ul style="list-style-type: none"> • n/a <p>Subgroups:</p> <ul style="list-style-type: none"> • Patient grade: <ul style="list-style-type: none"> ○ Good grade

		<ul style="list-style-type: none"> ○ Poor grade ● Cause of intracranial hypertension: <ul style="list-style-type: none"> ○ Haemotoma ○ Cerebral oedema 		
18.	Type and method of review	<input checked="" type="checkbox"/>	Intervention	
		<input type="checkbox"/>	Diagnostic	
		<input type="checkbox"/>	Prognostic	
		<input type="checkbox"/>	Qualitative	
		<input type="checkbox"/>	Epidemiologic	
		<input type="checkbox"/>	Service Delivery	
		<input type="checkbox"/>	Other (please specify)	
19.	Language	English		
20.	Country	England		
21.	Anticipated or actual start date			
22.	Anticipated completion date	3 February 2021		
23.	Stage of review at time of this submission	Review stage	Started	Completed
		Preliminary searches	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
		Piloting of the study selection process	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
		Formal screening of search results against eligibility criteria	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
		Data extraction	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
		Risk of bias (quality) assessment	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
		Data analysis	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
24.	Named contact	<p>5a. Named contact National Guideline Centre</p> <p>5b Named contact e-mail SAH@nice.org.uk</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>		
25.	Review team members	From the National Guideline Centre:		

		<ul style="list-style-type: none"> • Ms Gill Ritchie • Mr Ben Mayer • Mr Audrius Stonkus • Mr Vimal Bedia • Ms Emma Cowles • Ms Jill Cobb • Ms Amelia Unsworth
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
27.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
28.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual . Members of the guideline committee are available on the NICE website.
29.	Other registration details	
30.	Reference/URL for published protocol	
31.	Dissemination plans	<p>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</p> <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.
32.	Keywords	Subarachnoid, intracranial hypertension, raised intracranial pressure

33.	Details of existing review of same topic by same authors	None	
34.	Current review status	<input type="checkbox"/>	Ongoing
		<input type="checkbox"/>	Completed but not published
		<input type="checkbox"/>	Completed and published
		<input type="checkbox"/>	Completed, published and being updated
		<input type="checkbox"/>	Discontinued
35..	Additional information		
36.	Details of final publication	www.nice.org.uk	

Table 7: Health economic review protocol

Review question	All questions where health economic evidence applicable
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual.³⁹</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will decide based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p> <p>The health economist will be guided by the following hierarchies.</p> <p><i>Setting:</i></p> <ul style="list-style-type: none"> • UK NHS (most applicable). • OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden). • OECD countries with predominantly private health insurance systems (for example, Switzerland).

<ul style="list-style-type: none"> • Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations. <p><i>Health economic study type:</i></p> <ul style="list-style-type: none"> • Cost–utility analysis (most applicable). • Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis). • Comparative cost analysis. • Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations. <p><i>Year of analysis:</i></p> <ul style="list-style-type: none"> • The more recent the study, the more applicable it will be. • Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as ‘Not applicable’. • Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations. <p><i>Quality and relevance of effectiveness data used in the health economic analysis:</i></p> <ul style="list-style-type: none"> • The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.
--

Appendix B: Literature search strategies

This literature search strategy was used for the following reviews;

- What is the clinical and cost effectiveness of options for managing intracranial hypertension?

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual³⁹

For more information, please see the Methods Report published as part of the accompanying documents for this guideline.

B.1 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

Table 8: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 24 June 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies Diagnostic tests studies
Embase (OVID)	1974 – 24 June 2020	Exclusions Randomised controlled trials Systematic review studies

Database	Dates searched	Search filter used
		Observational studies Diagnostic tests studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 6 of 12 CENTRAL to 2020 Issue 6 of 12	None

Medline (Ovid) search terms

1.	exp Subarachnoid Hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp Intracranial Aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23
25.	6 not 24
26.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
27.	25 not 26
28.	limit 27 to English language
29.	exp "Sensitivity and Specificity"/
30.	(sensitivity or specificity).ti,ab.
31.	((pre test or pretest or post test) adj probability).ti,ab.
32.	(predictive value* or PPV or NPV).ti,ab.
33.	likelihood ratio*.ti,ab.
34.	likelihood function/
35.	((area under adj4 curve) or AUC).ti,ab.

36.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
37.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
38.	gold standard.ab.
39.	or/29-38
40.	Epidemiologic studies/
41.	Observational study/
42.	exp Cohort studies/
43.	(cohort adj (study or studies or analys* or data)).ti,ab.
44.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
45.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
46.	Controlled Before-After Studies/
47.	Historically Controlled Study/
48.	Interrupted Time Series Analysis/
49.	(before adj2 after adj2 (study or studies or data)).ti,ab.
50.	exp case control study/
51.	case control*.ti,ab.
52.	Cross-sectional studies/
53.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
54.	or/40-53
55.	Meta-Analysis/
56.	exp Meta-Analysis as Topic/
57.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
58.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
59.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
60.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
61.	(search* adj4 literature).ab.
62.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
63.	cochrane.jw.
64.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
65.	or/55-64
66.	randomized controlled trial.pt.
67.	controlled clinical trial.pt.
68.	randomi#ed.ti,ab.
69.	placebo.ab.
70.	randomly.ti,ab.
71.	Clinical Trials as topic.sh.
72.	trial.ti.
73.	or/66-72
74.	28 and (39 or 54 or 65 or 73)
75.	exp intracranial hypertension/ or hypertensive encephalopathy/ or pseudotumor cerebri/

76.	(intracranial hypertension or intra-cranial hypertension).ti,ab.
77.	(pseudotumor cerebri or hypertensive encephalopathy).ti,ab.
78.	((elevat* or increas*) adj (intracranial or intra-cranial) adj pressure).ti,ab.
79.	intracerebral hypertension.ti,ab.
80.	or/75-79
81.	74 and 80

Embase (Ovid) search terms

1.	*subarachnoid hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	Case report/ or Case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	Nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental animal/
19.	Animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)
25.	23 not 24
26.	limit 25 to English language
27.	exp "sensitivity and specificity"/
28.	(sensitivity or specificity).ti,ab.
29.	((pre test or pretest or post test) adj probability).ti,ab.
30.	(predictive value* or PPV or NPV).ti,ab.
31.	likelihood ratio*.ti,ab.
32.	((area under adj4 curve) or AUC).ti,ab.
33.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.
34.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
35.	diagnostic accuracy/

36.	diagnostic test accuracy study/
37.	gold standard.ab.
38.	or/27-37
39.	Clinical study/
40.	Observational study/
41.	family study/
42.	longitudinal study/
43.	retrospective study/
44.	prospective study/
45.	cohort analysis/
46.	follow-up/
47.	cohort*.ti,ab.
48.	46 and 47
49.	(cohort adj (study or studies or analys* or data)).ti,ab.
50.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
51.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
52.	(before adj2 after adj2 (study or studies or data)).ti,ab.
53.	exp case control study/
54.	case control*.ti,ab.
55.	cross-sectional study/
56.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
57.	or/39-45,48-56
58.	random*.ti,ab.
59.	factorial*.ti,ab.
60.	(crossover* or cross over*).ti,ab.
61.	((doubl* or singl*) adj blind*).ti,ab.
62.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
63.	crossover procedure/
64.	single blind procedure/
65.	randomized controlled trial/
66.	double blind procedure/
67.	or/58-66
68.	systematic review/
69.	meta-analysis/
70.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
71.	((systematic or evidence) adj3 (review* or overview*)).ti,ab.
72.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
73.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
74.	(search* adj4 literature).ab.
75.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
76.	cochrane.jw.
77.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.

78.	or/68-77
79.	26 and (38 or 57 or 67 or 78)
80.	exp intracranial hypertension/
81.	hypertension encephalopathy/
82.	brain pseudotumor/
83.	(intracranial hypertension or intra-cranial hypertension).ti,ab.
84.	(pseudotumor cerebri or hypertensive encephalopathy).ti,ab.
85.	((elevat* or increas*) adj (intracranial or intra-cranial) adj pressure).ti,ab.
86.	intracerebral hypertension.ti,ab.
87.	or/80-86
88.	79 and 87

Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Subarachnoid Hemorrhage] explode all trees
#2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) near/3 (hemorrhag* or haemorrhag* or bleed* or blood*)):ti,ab
#3.	(SAH or aSAH):ti,ab
#4.	MeSH descriptor: [Intracranial Aneurysm] explode all trees
#5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) near/3 (aneurysm* or aneurism* or hematoma* or haematoma*)):ti,ab
#6.	(OR #1-#5)
#7.	MeSH descriptor: [Intracranial Hypertension] explode all trees
#8.	MeSH descriptor: [Hypertensive Encephalopathy] explode all trees
#9.	MeSH descriptor: [Pseudotumor Cerebri] explode all trees
#10.	((intracranial NEXT hypertension) or (intra-cranial NEXT hypertension)):ti,ab
#11.	((pseudotumor NEXT cerebri) or (hypertensive NEXT encephalopathy)):ti,ab
#12.	((elevat* or increas*) NEXT (intracranial or intra-cranial) NEXT pressure):ti,ab
#13.	(intracerebral NEXT hypertension):ti,ab
#14.	(or #7-#13)
#15.	#6 and #14

B.2 Health Economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to subarachnoid haemorrhage population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase.

Table 9: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2003 – 23 June 2020	Exclusions Health economics studies
Embase	2003 – 23 June 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 23 June 2020	None

Database	Dates searched	Search filter used
	NHSEED - Inception to March 2015	

Medline (Ovid) search terms

1.	exp Subarachnoid Hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp Intracranial Aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23
25.	6 not 24
26.	limit 25 to English language
27.	Economics/
28.	Value of life/
29.	exp "Costs and Cost Analysis"/
30.	exp Economics, Hospital/
31.	exp Economics, Medical/
32.	Economics, Nursing/
33.	Economics, Pharmaceutical/
34.	exp "Fees and Charges"/
35.	exp Budgets/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.

39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/27-42
44.	26 and 43

Embase (Ovid) search terms

1.	subarachnoid hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	limit 23 to English language
25.	health economics/
26.	exp economic evaluation/
27.	exp health care cost/
28.	exp fee/
29.	budget/
30.	funding/
31.	budget*.ti,ab.
32.	cost*.ti.
33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.


35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/25-37
39.	24 and 38

NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Subarachnoid Hemorrhage EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Intracranial Hemorrhages EXPLODE ALL TREES
#3.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*))
#4.	((SAH or aSAH))
#5.	#1 OR #2 OR #3 OR #4
#6.	MeSH DESCRIPTOR Aneurysm EXPLODE ALL TREES
#7.	((aneurysm* or hematoma* or haematoma*))
#8.	#6 OR #7
#9.	MeSH DESCRIPTOR Intracranial Aneurysm EXPLODE ALL TREES
#10.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (aneurysm* or hematoma* or haematoma*))
#11.	#9 OR #10
#12.	MeSH DESCRIPTOR Aneurysm, ruptured
#13.	((ruptur* or weak* or brain or trauma*) adj3 (aneurysm* or hematoma* or haematoma*))
#14.	#12 OR #13
#15.	(#5 or #8 or #11 or #14)

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of managing intracranial hypertension



Appendix D: Clinical evidence tables

Study	Bentsen 2006 ⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=22)
Countries and setting	Conducted in Norway; Setting: single centre study, intensive care
Line of therapy	1st line
Duration of study	Intervention time : 210 minutes
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	Included intensive care patients with an acute spontaneous SAH with stable ICP in the range 10 -20 mmHg. They needed to be >18 yrs of age, sedated, mechanically ventilated, have stable hemodynamics and serum sodium of <160 mmol/L
Exclusion criteria	Not specified
Age, gender and ethnicity	Age - Mean (SD): Intervention group - 50.1(10.5); placebo - 55.2(10.8). Gender (M:F): 4/18. Ethnicity: not stated
Further population details	1. Cause of intracranial hypertension: Not stated / Unclear (spontaneous SAH). 2. Patient grade: Poor grade (Hunt and Hess median (range) intervention group - 5(3-5); place (2 -5)).
Indirectness of population	No indirectness
Interventions	(n=11) Intervention 1: Hypertonic saline. Hypertonic saline - was a 7.2% saline in 6% hydroxyethyl starch 200/0.5 solution (HyperHAES, Fresenius Kabi AG) The observation period lasted from 10 min before until 210 min after the start of the infusion. Need for rescue treatment was defined by treatment failure limits for ICP and CPP, which were an ICP of >20 mm HG and a CPP of <60 mmHG. Unless these limits were reached during the observation period, the ventilation variables were kept unaltered, the infusion rates vasopressors, analgesics, sedatives, and fluids were stable, the resistance in the external ventricular drainage (EVD) was unchanged, and the patients were neither stimulated or moved.. Duration 10 minutes before to 210 minutes after the infusion. Concurrent medication/care: n/a. Indirectness: No indirectness (n=11) Intervention 2: No treatment. Placebo - was 0.9% saline solution (Fresenius Kabi AG, Bad Homburg v.d.h),

	Germany. The observation period lasted from 10 mins before until 210 mins after the start of the infusion. Need for rescue treatment was defined by treatment failure limits for ICP and CPP, which were an ICP of >20 mm HG and a CPP of <60 mmHG. Unless these limits were reached during the observation period, the ventilation variables were kept unaltered, the infusion rates vasopressors, analgesics, sedatives, and fluids were stable, the resistance in the external ventricular drainage (EVD) was unchanged, and the patients were neither stimulated or moved.. Duration 10 minutes before to 210 minutes after the infusion. Concurrent medication/care: n/a. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: HYPERTONIC SALINE versus NO TREATMENT	
<p>Protocol outcome 1: Complications of procedure (any)</p> <p>- Actual outcome: intracranial pressure change score at 210 min after the intervention; Group 1: mean -3.3 (SD 2.6); n=11, Group 2: mean -0.3 (SD 1.3); n=11</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;</p>	
Protocol outcomes not reported by the study	Mortality ; Health and social quality of life ; Degree of disability or dependence in daily activities, (e.g. Modified Rankin Scale and patient-reported outcome measures) ; Subsequent subarachnoid haemorrhage ; Return to daily activity (e.g. work)

Study	Nagel 2009³⁸
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=18)
Countries and setting	Conducted in Germany; Setting: n/a
Line of therapy	1st line
Duration of study	Intervention + follow up: 12 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall: n/a
Subgroup analysis within study	Not applicable: n/a

Inclusion criteria	Any SAH patient developing intracranial hypertension with ICP values ≥ 20 mmHg for at least >6h after SAH and requiring treatment of elevated ICP was included. aSAH confirmed by CT; cerebral angiogram demonstrating intracranial aneurysm; patients underwent clipping followed by intraoperative insertion of the microdialysis catheter or patients underwent endovascular therapy of an aneurysm from the anterior circulation and additionally had an external ventricular drainage placed, so catheter placement through the existing burrhole allowed monitoring of the anterior cerebral artery territory.
Exclusion criteria	Patients were excluded if they were hemodynamically unstable, presented with fixed and dilated pupils on admission or died within 24 hours after admission
Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (SD): intervention group - 48(3.4) control group 52(3.5). Gender (M:F): 4/14. Ethnicity: not stated
Further population details	1. Cause of intracranial hypertension: Not applicable (SAH). 2. Patient grade: Not applicable (WFNS grade: intervention/comparison:(grade1 - 2/1; grade2 - 0/0; grade3 - 2/0; grade4 - 0/4; grade5 - 3/6) Fisher grade - intervention/comparison: (grade1 - 0/0; grade2 - 0/0; grade3 - 4/1; grade4 - 3/10).
Indirectness of population	No indirectness
Interventions	(n=7) Intervention 1: Surgical interventions - Decompressive Craniectomy . decompressive craniectomy - Hemicraniectomy was performed in median on day 4(2-6) after SAH, in 2 of the 7 patients early after SAH. in 4 patients (57%) a dilating pupil was observed shortly before hemicraniectomy.. Duration n/a. Concurrent medication/care: All patients underwent first line treatment. Second line treatment included barbiturate coma and forced hyperventilation in both groups. Moderate hyperventilation was performed in most patients (n=16, 89%) while forced hyperventilation was rare (n=5, 28%) most frequently, moderate hyperventilation was started on day 3 (10 out of 16 patients, 63 %, range 1-9 days) and forced hyperventilation on day 6 (4 of 5 patients, 80%, 1-8 days). Indirectness: No indirectness (n=11) Intervention 2: No treatment. no decompressive craniectomy. Duration n/a. Concurrent medication/care: All patients underwent first line treatment. Second line treatment included barbiturate coma and forced hyperventilation in both groups. Moderate hyperventilation was performed in most patients (n=16, 89%) while forced hyperventilation was rare (n=5, 28%) most frequently, moderate hyperventilation was started on day 3 (10 out of 16 patients, 63 %, range 1-9 days) and forced hyperventilation on day 6 (4 of 5 patients, 80%, 1-8 days). Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DECOMPRESSIVE CRANIECTOMY versus NO TREATMENT

Protocol outcome 1: Mortality

- Actual outcome: Mortality - Death while clinical stay at while clinical stay; Group 1: 4/7, Group 2: 8/11

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome: Mortality - Death 12 months at 12 months; Group 1: 5/7, Group 2: 8/11
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcome 2: Health and social quality of life


- Actual outcome: GOS (global outcome score (4-5) at 12 months; Group 1: 0/6, Group 2: 1/10
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 1
 - Actual outcome: GOS (global outcome score 3 at 12 months; Group 1: 1/6, Group 2: 1/10
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 1
 - Actual outcome: GOS (global outcome score 1-2 at 12 months; Group 1: 5/6, Group 2: 8/10
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 1

Protocol outcomes not reported by the study	Degree of disability or dependence in daily activities, (e.g. Modified Rankin Scale and patient-reported outcome measures) ; Subsequent subarachnoid haemorrhage ; Return to daily activity (e.g. work) ; Complications of procedure (any)
---	--

Appendix E: Forest plots

E.1 Hypertonic saline vs placebo

Figure 2: Change in intracranial pressure



E.2 Decompressive craniectomy vs no decompressive craniectomy

Figure 3: Mortality (death during hospitalisation)




Figure 4: Mortality (12 months)




Figure 5: GOS grade 1 – 2 (12 months). Scale 1-5; high score represents positive outcome




Figure 6: GOS grade 3 (12 months). Scale 1-5; high score represents positive outcome





Figure 7: GOS grade 4 – 5 (12 months). Scale 1-5; high score represents positive outcome



Appendix F: Minimal Important Difference for continuous outcomes

Table 10: Minimal important differences: Hypertonic saline versus placebo

Outcomes	Minimally important difference (MID)
Change in intracranial pressure	0.65

Appendix G: GRADE tables

Table 11: Clinical evidence profile: Hypertonic saline vs placebo (RCT)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Hypertonic Saline	Placebo	Relative (95% CI)	Absolute		
Intracranial Hypertension (follow-up mean 210 minutes; Better indicated by lower values)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	11	11	-	MD 3 lower (4.72 to 1.28 lower)	⊕⊕○○ LOW	IMPORTANT

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Table 12: Clinical evidence profile: Decompressive craniectomy vs no decompressive craniectomy (Observational study)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Surgery (decompressive craniectomy)	No surgery	Relative (95% CI)	Absolute		
mortality - death while clinical stay												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	study design ³	4/7 (57.1%)	8/11 (72.7%)	RR 0.79 (0.38 to 1.64)	153 fewer per 1000 (from 451 fewer to 465 more)	⊕○○○ VERY LOW	CRITICAL
Mortality - death 12 months (follow-up mean 12 months)												


1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	study design ³	5/7 (71.4%)	8/11 (72.7%)	Peto OR 13.08 (0.23 to 729.15)	not estimable	⊕○○○ VERY LOW	CRITICAL
GOS grade 1-2 after 12 months (follow-up mean 12 months)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	study design ³	5/6 (83.3%)	8/10 (80%)	RR 1.04 (0.65 to 1.67)	32 more per 1000 (from 280 fewer to 536 more)	⊕○○○ VERY LOW	CRITICAL
GOS grade 3 after 12 months (follow-up mean 12 months)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	study design ³	1/6 (16.7%)	1/10 (10%)	RR 1.67 (0.13 to 22)	67 more per 1000 (from 87 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
GOS grade 4-5 after 12 months (follow-up mean 12 months)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	study design ³	0/6 (0%)	1/10 (10%)	Peto OR 0.2 (0 to 11.57)	78 fewer per 1000 (from 100 fewer to 462 more)	⊕○○○ VERY LOW	CRITICAL

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Appendix H: Health economic evidence selection

Figure 8: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

Appendix I: Health economic evidence tables

None.

Appendix J: Excluded studies

J.1 Excluded clinical studies

Table 13: Studies excluded from the clinical review

Study	Exclusion reason
Al-Rawi 2010 ¹	Inappropriate study design – no comparison group
Alotaibi 2017 ²	Systematic review - references checked
Asaad 2019 ³	Inappropriate comparison – different EVD techniques
Bakar 2012 ⁴	Inappropriate population – traumatic brain injury
Battison 2005 ⁵	Inappropriate population – majority non SAH
Bentsen 2004 ⁷	Inappropriate study design - no comparison group
Bundgaard 2001 ⁸	Inappropriate population – brain tumours
Burger 2008 ⁹	Inappropriate population – traumatic brain injury
Buschmann 2007 ¹⁰	Inappropriate comparison – decompressive hemicraniectomy
Carandini 2018 ¹¹	Systematic review - references checked
Cole 2007 ¹²	Systematic review - references checked
Cossu 2016 ¹³	Systematic review - references checked
Dai 2005 ¹⁵	Inappropriate intervention – nimodipine
D'Ambrosio 2005 ¹⁴	Inappropriate comparison – hemicraniectomy
Dorfer 2010 ¹⁶	Inappropriate comparison - retrospective study comparing clipping + decompressive hemicraniectomy to embolization + decompressive hemicraniectomy or insufficient decompressive hemicraniectomy
Eide 2011 ¹⁷	Inappropriate comparison – different ICP management techniques
Froelich 2009 ¹⁸	Inappropriate population – neuro-critically ill people
Graetz 2010 ¹⁹	Inappropriate comparison – ICP management
Hauer 2011 ²⁰	Inappropriate population – cerebrovascular disease
Hayashi 1988 ²¹	Inappropriate study design – same intervention between groups
Helbok 2011 ²²	Inappropriate study design – before and after study
Heuer 2004 ²³	Inappropriate study design - no comparison group
Horn 1999 ²⁴	Inappropriate population – traumatic brain injury
Infanti 2008 ²⁵	Inappropriate study design - literature review
Jagersberg 2010 ²⁶	Inappropriate population – traumatic brain injury
Karnatovskaia,2014 ²⁷	Inappropriate comparison - comparison of temperature management
Kim, 2015 ²⁸	Inappropriate population – traumatic brain injury
Lewandowski-Belfer 2014 ²⁹	Inappropriate study design – no comparison group
Lewis 2014 ³⁰	Inappropriate study design - no comparison group
Lo 2017 ³¹	Inappropriate population – cerebrovascular disease
Malmivaara 2011 ³²	Inappropriate study design - no comparison group
Munch 1998 ³³	Inappropriate population – severe head injury
Murad 2008 ³⁴	Inappropriate population – traumatic brain injury
Murad 2011 ³⁵	Inappropriate study design – no comparison group
Myles 1996 ³⁶	Inappropriate study design – review article

Study	Exclusion reason
Nagel 2009 ³⁷	Inappropriate comparison – same intervention for all groups
Otani 2008 ⁴²	Inappropriate study design – before and after study
Otani 2013 ⁴¹	Inappropriate study design – no comparison group
Pasarikovski 2017 ⁴³	Systematic review - references checked
Qureshi, 2000 ⁴⁴	Inappropriate study design - literature review
Ravishankar 2020 ⁴⁵	Literature review - references checked
Reddy 2009 ⁴⁶	Systematic review - references checked
Roitberg 2008 ⁴⁷	Inappropriate population – mixed population (ICH or SAH)
Schirmer 2007 ⁴⁸	Inappropriate study design – before and after study
Schwarz 1998 ⁴⁹	Inappropriate study design – no relevant outcomes
Shi 2000 ⁵⁰	Not in English
Stocchetti 2000 ⁵¹	Inappropriate population – head injury
Takeuchi 2011 ⁵²	Inappropriate comparison/ inappropriate population – prognostic study for non traumatic ICH
Tanrikulu 2015 ⁵³	Inappropriate population – mixed population (MCA infarction/haemorrhage/trauma)
Thenier-Villa 2020 ⁵⁴	Inappropriate comparison – rebleed versus no rebleed, all participants had EVD
Tietjen, 1996 ⁵⁵	Inappropriate study design - literature review
Tuetttenberg 2009 ⁵⁶	Inappropriate population - mixed population (traumatic brain injury and SAH)
Tuteja, 2019 ⁵⁷	inappropriate population/inappropriate comparison – spontaneous ICH
Uozumi 2014 ⁵⁸	Inappropriate population – no raised ICP
Villa 2012 ⁵⁹	Inappropriate population – raised ICP excluded
Wang 2017 ⁶⁰	Inappropriate comparison – nursing assessment
Witherspoon, 2017 ⁶¹	Inappropriate study design - literature review
Won 2008 ⁶²	Inappropriate study design – no comparison group
Woodcock 1982 ⁶³	Inappropriate study design/ inappropriate intervention – before and after study for barbiturates
Wykes 2015 ⁶⁴	Inappropriate study design - literature review
Xu 2018 ⁶⁵	Inappropriate population – subdural haematoma
Yang 2016 ⁶⁶	Inappropriate comparison – craniotomy techniques
Zahid 2012 ⁶⁷	Inappropriate comparison – temperature control compared to surgery
Zhao 2015 ⁶⁸	Inappropriate population – no raised ICP

J.2 Excluded health economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.

Table 14: Studies excluded from the health economic review

Reference	Reason for exclusion
None.	

Appendix K: Research recommendations

K.1 Intracranial hypertension

Research question: What is the impact of routine monitoring of intracranial hypertension on subsequent management and outcome in people with aneurysmal subarachnoid haemorrhage who are unconscious or ventilated on an intensive care unit?

Why this is important:

In people with subarachnoid haemorrhage the pressure inside the skull may be increased by hydrocephalus, haematoma or cerebral oedema. Raised intracranial pressure (intracranial hypertension) can impede blood flow to the brain even if the systemic blood pressure is normal. Raised intracranial pressure can be inferred in people with cerebral oedema or mass lesions on a CT head scan, particularly if focal brain herniation is present, but can only be established definitively by invasive measurement. This can be done by insertion of a pressure sensor into the cranial cavity, or by pressure measurement from a ventricular drain, and is generally only done in people with aSAH who are admitted to an intensive care unit. Current practice varies widely, and some clinicians have a low threshold for intra-cranial pressure monitoring and base management decisions on the intra-cranial pressure, while other clinicians determine management without measuring intra-cranial pressure.

Criteria for selecting priority research recommendations:

PICO question	<p>Population: Adults (16 and older) with a confirmed subarachnoid haemorrhage caused by a ruptured aneurysm who are unconscious or ventilated on an intensive care unit.</p> <p>Intervention(s):</p> <ul style="list-style-type: none">• Routine monitoring of ICP<ul style="list-style-type: none">○ Direct pressure measurement/intracranial pressure (ICP) monitoring• Detection of raised ICP will facilitate early use of interventions to manage ICP including:<ul style="list-style-type: none">○ Hypertonic saline○ External ventricular drain○ Hypertensive therapy○ any other protocol therapy to reduce ICP. <p>Comparison:</p> <ul style="list-style-type: none">• No routine monitoring for ICP. <p>Interventions to manage ICP may still be used but will not be directed by direct monitoring of ICP.</p> <p>Outcome(s):</p> <ul style="list-style-type: none">• Mortality• Health and social-related quality of life (any validated measure)• Degree of disability or dependence in daily activities, (any validated measure e.g. Modified Rankin Scale and patient-reported outcome measures)• Interventions to manage intracranial hypertension• Return to daily activity (e.g. work, driving)• Complications of intervention (any)
----------------------	---

Importance to patients or the population	The anticipated benefit of monitoring intracranial pressure and treating any intracranial hypertension is to reduce the risk of neurological deterioration and mortality. The anticipated benefit of not measuring pressure is to avoid the procedure-related morbidity associated with doing so.
Relevance to NICE guidance	There is currently no guidance on the direct monitoring and subsequent management of raised intracranial pressure in people with SAH. Further research may guidance to be developed within this area.
Relevance to the NHS	Practice for the monitoring and subsequent management of raised intracranial pressure currently varies across the UK. The proposed research may help to reduce this variation and inform the design of a randomised trial.
National priorities	Not relevant to a national priority area.
Current evidence base	There is little evidence on diagnosing and treating intracranial hypertension. The diagnostic accuracies of transcranial doppler and ultrasound measurement of optic nerve sheath diameter were considered too low by the committee for reliable detection of intracranial hypertension when compared with direct intracranial pressure measurement. The committee also highlighted that there is no evidence that interventions to lower intracranial pressure improve clinical outcome.
Equality	No equality issues
Study design	Data to be collected as part of a registry study.
Timeframe	Evidence should be carried out within 3-5 years to allow for a sufficient collection of data and follow-up time.
Feasibility	This research is considered to be feasible.
Other comments	The committee noted that currently clinicians may not have equipoise to randomise patients to routine monitoring and no routine monitoring, and a RCT in this area currently may not be feasible. The committee agreed that a registry-based study could inform practice and the design of future definitive research.
Importance	Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates.